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Overview
Scientific findings and up-to-date evidence are needed for sound policymaking at local, national 
and EU level. Research can help answer many policy questions by investigating which interventions 
or combination of interventions may be more appropriate to help reduce drug problems. Research 
can also assess the cost-effectiveness of various alternative interventions and suggest innovative 
ways to increase effectiveness.
Both the European Commission and the Member States have been investing in drug-related 
research and promoting the development of a wider knowledge base to underpin drug policy. 
However, there has been no consistent approach at European level to identifying and prioritising 
research topics.
The EMCDDA has been monitoring drug-related research since 2007, as part of its mandate to 
provide ‘the Community and its Member States with factual, objective, reliable and comparable 
information at European level concerning drugs and drug addiction and their consequences’ (1). 
The agency has developed a methodology to analyse research activity on the basis of the studies 
cited by Reitox national focal points in their Reitox national reports.
This Thematic paper therefore draws from a variety of sources, which include analysis of the yearly 
national reports submitted to the EMCDDA by the Reitox national focal points over the period 
2008–10, projects funded through different European Commission research and drug-related 
programmes, and Council and Commission documents focusing on this topic. It aims to update the 
EMCDDA Selected issue on national drug-related research in Europe (EMCDDA, 2008), by 
reporting on recent developments and current challenges, and by suggesting future opportunities in 
this field.
(1)  Regulation (EC) No 1920/2006 of 12 December 2006 on the European Monitoring Centre for Drugs and Drug 
Addiction (recast).
emcdda.europa.eu
4
Drug-related research in Europe: 
recent developments and future perspectives
Introduction
Interest in drug-related research at European Union (EU) level as a topic of policy relevance can be 
traced back to the 1996 joint seminar on ‘Drug research-related initiatives in the European Union’, 
organised by the European Commission (EC), where representatives of Member States, the 
EMCDDA, the Reitox network and individual researchers were invited to discuss national research 
situations and needs, and to contribute with drug-related topics to the Fifth research and technical 
development framework programme (EMCDDA, 2008). This initiative followed Research Council 
conclusions on ‘The role of research in the fight against drugs’, which had called upon the 
Commission to consider drug-related research topics when preparing the Fifth Framework 
Programme and to identify, in consultation with the Member States, measures to enhance the 
research effort at Member State and Community level on this topic (Research Council, 1996).
The conclusions of the 1996 joint seminar addressed issues that are still relevant today, such as the 
value of cross-national collaboration, the role of the multidisciplinary approach, the importance of 
coordination arrangements and the sustainability of funding, the need for a wider availability and 
dissemination of research results, and the necessity to increase the dialogue between policymakers 
and researchers (Kenis, 1997).
Although there is no generally agreed definition of what constitutes drug-related research 
(Bühringer et al., 2009), research is now mentioned in the drug strategies and action plans of most 
Member States, and the need for evidence-based policy is highlighted in many of them (EMCDDA, 
2008). The following section discusses definitions of drug-related research, and provides examples 
of recent or ongoing research at European level.
Research is mentioned in the 2005–12 EU drugs strategy under the cross-cutting theme ‘information 
and research needs’, which calls for a ‘better understanding of the drugs problem and the 
development of an optimal response to it through a measurable and sustainable improvement in the 
knowledge base and knowledge infrastructure’. The strategy also identifies as one of its priorities 
that ‘EU action plans should include priority research topics to be fostered at EU level, taking into 
account the rapid evolution of the drugs problem. Large-scale exchanges and dissemination of 
research results, experiences and good practices should be promoted at Member State and EU 
level’ (Council of the European Union, 2004). The action plans (2005–08 and 2009–12) follow 
suit, with specific actions to promote research at different levels and foster information exchange to 
support policymaking (Council of the European Union, 2005; 2008). In ‘Increasing the European 
knowledge base on illicit drugs’ the main initiatives taken at European level to achieve the objective 
of the EU strategy are described.
In a 2008 Selected issue on national drug-related research, the EMCDDA described the situation in 
Europe in 2007 and the main developments that had taken place since the 1996 joint seminar. The 
review concluded that, comparing the 1996 and 2007 findings, the situation concerning drug-
related research in Member States had developed in a positive way, particularly concerning the 
area of prevalence, incidence and patterns of use, in which all countries had recent or ongoing 
projects by 2007. It also confirmed the three-stage ‘sequencing’ in the development of national 
drug-related research (Kenis, 1997): countries that report a more recent tradition of drug-related 
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research mainly focus on epidemiological surveys and indicators, and other quantitative methods 
for estimating drug use. Later, research requirements expand to include not only the use of drugs, 
drug-related harm and the study of services, but also to the evaluation of policy and measures. In a 
third stage, research areas and topics may be further diversified to include social, psychological, 
medical and biological mechanisms behind drug use. The report further concluded that the 
dissemination of research had also developed significantly since 1996, with an increase in the 
number of drug research journals in Europe and the availability of new dissemination channels, 
notably those based on the Internet. Finally, it suggested that regular overviews and monitoring of 
drug-related research could be helpful in keeping stakeholders informed of developments in the 
area and in identifying limitations, gaps and priorities for the future.
Since the publication of the Selected issue, the EMCDDA has developed a methodology for 
collecting and analysing information on national drug-related research and disseminating it through 
the Annual report and a dedicated website (2). The methodology and results of the exercises are 
presented and discussed in the fifth section of this report (p. 13).
In 2008, a study entitled ‘Comparative analysis of research into illicit drugs in the European Union’ 
(Bühringer et al., 2009) was carried out for the European Commission, with the aims: of mapping 
and analysing key research areas, disciplines and trends as well as the capacity, infrastructure and 
model of coordination of drug-related research in the Member States, and at European and 
international level; to describe, for comparative purposes, the same topics in Australia, Canada 
and the United States; and to identify strengths and weaknesses in EU drug-related research as well 
as gaps in the knowledge infrastructure in this field, and to assess options for strengthening — if 
necessary — the drug-related research infrastructure.
(2)  EMCDDA drug-related research thematic page.
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Drug-related research: definitions and 
implementation aspects
Defining and categorising drug-related research is not an easy task. The definition should take into 
account different aspects of the field, such as the scope of the study (e.g. are all psychoactive 
substances involved, or only illicit ones?) and the approach (e.g. does monitoring equal reseach?). 
For analytical purposes, it is also necessary to consider the research discipline or, in the case of 
multidisciplinary studies, disicplines involved, and to develop a typology of drug-related research 
topics.
Bühringer et al. (2009) stated that there was still ‘no internationally accepted definition of research’ 
and opted for defining research as performing a methodological study, in order to test a hypothesis 
or answer a specific question. A definition of the scope of the object was not needed, since the 
study only included ‘research into illicit drugs’, but a reference was made to narrowing down the 
scope of the approach to ‘the use of scientifically accepted methods and procedures’, leaving out 
of the definition other ‘activities such as monitoring or compiling best-practice programmes’, which 
also aim at ‘the gathering of information to answer a question and advance knowledge’.
Considering multidisciplinarity, ‘just as drug use cuts across broad sections of society, so 
drug-related research embraces numerous research disciplines, such as public health, psychiatry 
and psychology, sociology, medicine, law, criminology, political science and economics’ 
(EMCDDA, 2008). The EMCDDA study further suggested that ‘the drugs phenomenon needs to 
be studied with a comprehensive approach’. In fact, the multidisciplinary approach is generally 
accepted as a means to build understanding of the complex phenomenon of drug use and 
addiction (Kenis, 1997; Miller et al., 2010; Ritter, 2006). However, concerns are often 
expressed that, in practice, applying multidisciplinary approaches is not always straightforward 
or feasible (EMCDDA, 2008).
For the purpose of this Thematic paper, a definition that tries to bring together these different 
elements is adopted: drug-related research involves performing a study on illicit drugs (3), which 
may involve a range of disciplines, through the use of scientifically accepted methods and 
procedures, in order to test a hypothesis or answer a specific question.
Approaches to categorising drug-related research include a typology developed by the Council of 
Europe’s Pompidou Group, which classifies studies under three broad headings: social drug 
research, psychological drug research and biomedical drug research (Muscat et al., 2009). 
Bühringer et al. (2009) proposed four categories for research on illicit drugs in the European 
Union: understanding drug use behaviour (an area that includes basic research — mechanisms and 
aetiology — and epidemiology); demand reduction; supply reduction; and policy analysis. The 
EMCDDA suggested its own categories (EMCDDA, 2008), which are closer, but not identical, to 
those of Bühringer et al. (2009), and which were further developed in 2009, as described in a 
later section of the current paper (p. 14).
(3) ‘Illicit narcotic and psychoactive substances’ as defined by the UN drug-related conventions.
emcdda.europa.eu
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To understand how the different types of research are implemented in practice, it is important to 
look into how research is carried out and funded, both at national and European level.
Research in Member States
In 2008, Reitox national focal points reported that about half of the drug-related research projects 
carried out in European countries were conducted in universities and one-third by public or 
governmental organisations. Specialised research centres exist in some countries, and some of 
these centres have a focus on social research whereas others have their origins in psychiatric 
clinics. Interdisciplinary issue-oriented, national research networks with sustainable funding do exist 
in a few countries, but cooperation between institutes and researchers at European level mainly 
takes place in the framework of EU-funded and multinational projects, such as the European school 
survey project on alcohol and drugs (ESPAD), one of the longer-standing examples of collaborative 
drug-related research in Europe (Bühringer et al., 2009; EMCDDA, 2008).
The major funding sources in all Member States are national public agencies, usually linked to the 
ministries of health, science, education, justice and social or interior affairs (Bühringer et al., 2009). 
In some instances, specific, time-limited national drug-related research programmes, possibly linked 
to the implementation of a national strategy or action plan, have helped build up research 
networks, increased the capacity and overall quantity and quality of research, but scientific 
production has not always been sustained after the programme stopped (EMCDDA, 2008). One of 
the more sustainable examples of a specific funding programme linked to the implementation of a 
national policy is the research programme in support of the federal drugs policy document under 
the Belgian federal programme BELSPO, which has been running since 2002 (BELSPO, 2012).
This situation, reported in 2008 and 2009, does not seem to have changed dramatically, as very 
few updates were reported to the EMCDDA between 2009 and 2011.
Research at EU level
At EU level, the European Commission’s 7th Framework programme for research and development 
(2007–13), commonly referred to as FP7, and particularly its ‘Cooperation’ programme, support 
drug-related research through calls for research proposals that are of relevance to the drugs 
field (4). In this context, specific reference should be made to the more recently funded projects, 
which include: Access to opioid medication in Europe (ATOME), Psychosocial factors relevant to 
brain disorders in Europe (PARADISE), Size and burden of mental disorders and other disorders of 
the brain in Europe, Addictions and lifestyles in contemporary Europe — reframing addictions 
project (ALICE-RAP) and Grasping the links in the chain: understanding the unintended 
consequences of international counter-narcotics measures for the EU (LINKSCH). One particularly 
interesting funding mechanism that is made available by FP7 is the setting up of ERA-NETs — 
European networks for particular research areas. ERA-NETs are a funding tool ‘to develop and 
(4)  An overview of EU-funded research projects over the last 10 years, including the ones mentioned in this Thematic 
paper, is available at the EMCDDA research web area.
emcdda.europa.eu
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strengthen the coordination of national and regional research programmes’. Under the ERA-NET 
scheme, national and regional authorities identify research programmes they wish to coordinate or 
open up mutually. The participants in these actions are therefore programme ‘owners’ (typically 
ministries or regional authorities defining research programmes) or programme ‘managers’ (such as 
research councils or other research funding agencies managing research programmes) (CORDIS, 
2012). Under the 2012 work programme of the cooperation area ‘social sciences and humanities’, 
a call was launched for the setting up of an ERA-NET on the topic of ‘drug demand and supply 
reduction’. A European consortium applied to this call with a project called ERANID (ERA-NET on 
illicit drugs), which aims to promote integrated European research on illicit drugs. If funded, this 
project could promote a coordinated approach to funding drug-related research in Europe.
The European Commission is also funding other drug-related studies as part of different 
programmes, such as the ‘Drug prevention and information programme‘, the ‘Prevention of and fight 
against crime programme‘ and the ‘Health programme‘, which may yield important insights into the 
challenges facing Member States in this field and contribute to the implementation of the current EU 
strategy and action plan on drugs. Projects such as ‘New methodological tools for policy and 
programme evaluation’, ‘Further analysis of the EU illicit drugs market and responses’ and 
‘European standards in evidence for drug prevention’ are funded by the European Commission with 
the explicit purpose, among others, of contributing to the improvement of information on drug use 
and to generating and disseminating health information and knowledge.
Bühringer et al. (2009) found that most of the European Commission funding instruments, however, 
were underutilised, partly because many researchers lack knowledge and experience of them, but 
also because specific drug-related funding opportunities were rarely published. Bühringer et al. 
(2009) also suggested a wider use of the FP7 Marie-Curie fellowship programme, and of the 
funding mechanisms under COST (European Cooperation in Science and Technology) and the 
European Science Foundation.
Dissemination of findings
Another important step of the cycle needs to be addressed here, as ‘science is meaningless unless 
the lessons learnt from it are communicated’ (Miller et al., 2010). The dissemination of research 
findings in the drugs field, as in science in general, is mainly achieved through the publication of 
articles in peer-reviewed journals (Sánchez-Carbonell et al., 2005). Twenty-eight peer-reviewed 
journals that are specialised in drug research are published in Europe (5); around 20 of those are 
published in languages other than English, but with English abstracts. Much drug-related research 
carried out in Europe is also published in journals based in North America or in journals covering 
general disciplines such as medicine, psychology, sociology, policy, criminology, law, toxicology 
and economics (EMCDDA, 2008).
In Europe, the publication of drug-related research is unevenly distributed between countries, with 
western European countries, in particular the United Kingdom, in the lead. Research findings 
funded by governmental or non-governmental organisations are often published in hard copy or on 
(5)  See the EMCDDA drug-related research webpage.
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the websites of these organisations, and in their national languages. Most of this information never 
makes its way into the scientific literature databases and therefore remains available only to a 
limited audience (EMCDDA, 2008).
The existence of language barriers and the need to improve the visibility and accessibility of 
European research findings published in non-English language scientific journals were also 
mentioned by Bühringer et al. (2009), who called for the creation of a common European database 
for drug-related research projects, so that core information on all research activities could be 
centralised and made available, at least in English.
emcdda.europa.eu
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Increasing the European knowledge base 
on illicit drugs
The study ‘Comparative analysis of research into illicit drugs in the European Union’ (Bühringer et 
al., 2009) concluded that research capacity, overall quality and funding availability varied widely 
in the European Union, and that there was a considerable need for capacity building and for 
funding to cover a broader range of policy areas linked to the EU drug action plan. It also found 
that, although comprehensive expertise existed in Member States, improved data comparability 
between countries and increased visibility of research should be pursued.
Taking the main research areas of ‘understanding drug use’, ‘demand reduction’, ‘supply reduction’ 
and ‘policy’, Bühringer et al. (2009) found a considerable difference between the identified 
national research priorities and the number of studies available, particularly in the areas of ‘supply 
reduction’ and ‘policy’, which seemed to be relatively under-researched, or for which findings were 
not available. Under ‘demand reduction’, prevention was the least-researched area, although most 
countries considered it to be a national priority. For the ‘understanding drug use’ research area, the 
major weakness was a lack of studies in a number of areas, including on the relative contribution 
of biological and psychological factors, and on cultural, economic, legal and social factors. 
Compared to other study areas, research on the epidemiology of drug use was found to be more 
common and well-established in most countries, a finding in line with the conclusions of the 
Selected issue (EMCDDA, 2008).
Participation in European research activities was found to vary considerably between countries, 
with the majority of the eastern European countries being under-represented in EC-funded projects, 
and much of the international cooperation taking place on an informal basis. However, the study 
emphasised that drug-related research can be facilitated by European and international networks 
of researchers.
The Council of the European Union further discussed the topic of drug-related research at the 
Council’s Horizontal Working Party on Drugs. In late 2009, the Swedish Presidency issued Council 
Conclusions on ‘strengthening EU research capacity on illicit drugs’ (Council of the European Union, 
2009).
This document identified the cause and nature of drug problems and evaluation research as the 
main EU research priorities in the field of illicit drugs. It invited Member States to strengthen their 
research capacity and coordination mechanisms, to further explore opportunities provided by FP7, 
and to actively contribute to consultations on the future European research policy and the future 
objectives of drug-related research under the next EU drugs strategy.
The Council also established an annual exchange on drug-related research at EU level within the 
framework of the Horizontal Drugs Group (HDG) and with the contribution of the EMCDDA. Such 
exchange already took place in 2010 and 2011, and the HDG acknowledged the need to improve 
access to research findings for policymakers and professionals, and called on the EMCDDA to 
provide and disseminate, via its thematic web area on research and its Best practice portal, 
drug-related research information and findings.
emcdda.europa.eu
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At the same time, research activities have received support from FP7 and other financial 
programmes, as reported in the previous section. However, concerns have been voiced that 
funding for addiction research has been stagnating in Europe, where it is below the levels provided 
in countries such as China and the United States, at least in some specific areas (Helinski and 
Spanagel, 2011).
Increased visibility of and accessibility to research findings would also contribute to the expansion 
of the European knowledge base on drugs within and beyond the academic world. An important 
initiative for drug-related research was the publication ‘Projects, studies and research on illicit drugs 
funded by the European Commission 2007–10’ (European Commission, 2011). This report provided 
a comprehensive overview of projects funded under the ‘Drug prevention and information 
programme’, ‘The prevention of and fight against crime programme’, the ‘Health programme’ and 
FP7, including — where available — a summary of actual or expected results.
The Pompidou Group maintains an online research register intended for the research community, 
where researchers can insert the information they want to share concerning their projects and 
consult the information provided by other researchers, research institutes, funding agencies, calls 
for collaboration and calls for tender. The register contains information on 629 individuals and 145 
research projects (Pompidou Group, 2012). However, there is no independent quality check on the 
information entered, which limits the usefulness of this initiative (Bühringer et al., 2009).
In a more general context, the European Commission-funded initiative ‘Open access infrastructure 
for research in Europe’ (OpenAIRE) aims at supporting the implementation of a free, rapid and 
transparent access to European research outputs and findings. Recipients of grants from the 
European Research Council or from most of the research areas under FP7 are obliged to make their 
publications and other outputs available on the OpenAIRE website. Although still new, this 
repository may prove to be an important tool for accessing, disseminating and transferring into 
practice drug-related research findings. It may also help to build better research activity indicators, 
as researchers themselves seem to agree that published outputs of research projects should be the 
basis for assessing the research situation in Europe (Bühringer et al., 2009; Helinski and Spanagel, 
2011; Sánchez-Carbonell et al., 2005).
Two European research networks that cover drugs and addiction were set up in 2010: the 
European Society for Prevention Research and the European Federation of Addiction Societies. In 
addition, a third one, ERANID (see ‘Drug-related research: definitions and implementation aspects’), 
should be formalised before the end of 2012. Such networks may prove to be a way forward for 
overcoming limitations and gaps in drug-related research, further disseminate research findings, 
and influence priorities and the allocation of funding (EMCDDA, 2008; Mann, 2012).
emcdda.europa.eu
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Horizon 2020, the European Union’s new programme for research and 
innovation
Horizon 2020 will provide the framework for European drug-related research in the future. It will address 
research and innovation together, with the aim of contributing to tackling societal challenges, as a basis for 
sustainable economic growth. This focus has the potential to promote cross-cutting coordination and 
coherence in funding for multidisciplinary topics, such as drug-related research.
In the public consultation held by the Commission on the EU framework for research and innovation, the 
EMCDDA’s Scientific Committee presented detailed recommendations (EMCDDA’s Scientific Committee, 
2011) under the following general priorities:
1.  EU research and innovation funding that maximises the benefits of acting at the EU level is vital, 
particularly in cross-border research on societal challenges, such as drug-related research. There is a 
need for well-coordinated research across the European Union, where common research questions are 
answered. The use of appropriate methods, designs and instruments, both qualitative and quantitative, 
facilitates the generation of more statistically powerful samples and allows for robust comparisons.
2.  The future common strategic framework can only make EU research and innovation funding more 
attractive and easy to access for participants if the whole process is made more transparent and easier to 
follow up on, even by inexperienced EC-funding applicants.
3.  EU funding needs to improve in terms of how best to cover the full innovation cycle, which goes from 
research to practice, by analysing and strategically prioritising the research topics and gaps in each 
area, coordinating research calls in a complementary way, especially for cross-cutting areas, and by 
further promoting the dissemination and implementation of research findings.
4.  Greater priority needs to be given to researcher-initiated projects. Further coordination needs to be 
promoted on research topics and findings between the bottom-up research projects, currently funded 
under the European Research Council, and the top-down ones, currently funded under the cooperation 
programmes, so that the advantages of both approaches can be optimised and world class excellence in 
research is achieved.
5.  Indicators for monitoring EU research and innovation funding should continue to focus on scientific quality 
but also on dissemination of findings, capacity building and knowledge transfer.
emcdda.europa.eu
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Monitoring drug-related research in Europe using 
Reitox national reports
Gathering information on research that is funded and carried out at national level is an important 
part of the monitoring activity of the EMCDDA. Currently, there is no systematic inventory of 
drug-related research activities in Europe. In this section, we present an analysis that aims to give 
an indirect assessment of this area. Among other uses, monitoring and disseminating information 
on drug-related research may help countries: to identify knowledge gaps; to know whether the 
funded areas are consistent with the policy priorities; and to know where to look for potential 
partners, scientific advisors, or both for their own projects.
Collecting and analysing data on drug-related research
Since the publication of the Selected issue on drug-related research in Europe (EMCDDA, 2008), 
the EMCDDA has developed a new methodology to collect information on drug-related research 
by analysing the full text of the yearly Reitox national reports and using this information as a proxy 
for relevant drug-related research conducted at national level. After discussions with representatives 
of the Reitox network, during an expert meeting in 2009 (6), the following methodology was 
adopted.
Step 1 — data collection
The full text of the annual Reitox national reports was searched for four keywords: survey, research, 
study and studies. Information about research and related bibliographic references cited in the text 
that pertain to the period up to two years before the date of the National report were collected 
and inserted in a database. In addition, relevant web links, where available, were also collected 
and tested, and broken links were excluded.
Each study was recorded in the database only once, regardless of how many times it was 
mentioned in the original text. References to EC-funded projects carried out by several countries 
were recorded only once, namely in the coordinating country (e.g. DRUID, coordinated by 
Germany), except when there was a reference to the use of national data. European projects 
funded nationally were recorded for each country that mentioned them (e.g. ESPAD).
Research mentioned in the following contexts was excluded from the main database: national drug 
strategy documents; implementation of research findings in training, manuals and guidelines; 
establishing of new research agencies; public spending on drug-related research; press reports. 
(6)  The meeting took place at the EMCDDA in October 2009 with the participation of EMCDDA staff, invited experts 
from ECDC and BELSPO and the Reitox national focal points of Germany, Ireland, Estonia and Portugal. The 
minutes were afterwards made available to the entire Reitox network with an opportunity for further input from 
those who had not attended the meeting.
emcdda.europa.eu
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Findings for which a study could not be identified or which had anecdotal origins were either 
excluded or recorded into a general information list (see below) for each country.
Step 2 — data validation
Based on the information collected in Step 1, each Reitox national focal point received a draft, 
summarised list of identified studies. They were given an opportunity to send comments, updates 
and corrections before information on drug-related research was published. The database and 
additional lists were corrected according to the feedback received during the validation process.
Step 3 — data analysis
Several approaches may be used to classify drug-related research (Bühringer et al., 2009; 
Sánchez-Carbonell et al., 2005). For the 2008 Selected issue, the EMCDDA suggested five 
categories that give a comprehensive picture of the main areas involved and could serve decision-
makers well. The list of categories was compiled based on a previous attempt (Kenis, 1997), as 
well as an informal consultation with members of the EMCDDA Scientific Committee, and experts’ 
opinions (see above). In addition, two categories were added: one on markets and supply (outside 
the scope of the 2008 publication) and another on methodology issues, which are often linked to 
national initiatives to implement the EMCDDA key epidemiological indicators or other types of 
requested data. The seven research categories are:
1.  Prevalence, incidence and patterns of drug use — this category includes (general and specific, 
including school) population surveys, estimates of problem drug use, studies on the 
characteristics of drug users or patterns of drug use;
2.  Responses to the drug situation — this category includes studies on demand reduction 
interventions such as the evaluation of interventions (treatment, prevention, etc.), the 
implementation of policies and laws, estimates of public expenditure and other economic topics;
3.  Determinants of drug use — this category includes studies on risk and protective factors for drug 
use;
4.  Consequences of drug use — this category includes studies on health, social and legal 
consequences of drug use;
5.  Mechanisms of drug use and effects — this category includes neurobiological, pharmacological 
and behavioural studies, as well as research on the aetiology and developments of drug use;
6.  Supply and markets — this category includes studies on supply reduction interventions, such as 
law enforcement interventions, as well as studies on market characteristics, such as the 
availability and purity of drugs;
7.  Methodology issues — this category includes feasibility and validity studies on the 
implementation of EMCDDA indicators and comparisons between different methodologies.
emcdda.europa.eu
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Drug-related research studies were analysed and categorised in the context in which they 
appeared in each Reitox national report. General information on drug-related research, referred to 
above, was not categorised.
The approach described here was applied to the Reitox national reports for the years 2008, 2009 
and 2010.
Results of the analysis
For the period 2008–10, a total of 1 808 references to ongoing studies in the Reitox national 
reports were extracted and categorised. The results reveal that, similarly to the findings presented 
in the 2008 EMCDDA Selected issue, the majority of research was conducted in three areas: on 
responses; on consequences of drug use; and on prevalence, incidence or patterns of drug use 
(Figure 1). Studies on supply and markets, determinants of drug use and risk and protective 
factors, mechanisms of drug use and effects, and methodology aspects made up only 16% of all 
studies.
The findings also reveal that the total number of reported references increased every year, both 
overall and in the majority of research areas (Figure 2). The average number of studies mentioned 
in any national report increased from 14.3 in 2008, to 23.1 in 2009 and 26.3 in 2010. There was, 
however, large variation among countries: the minimum number of studies mentioned in a national 
report in the three reporting years — reported by different countries — was three, while the 
maximum number of studies mentioned in a national report — always by the United Kingdom — 
increased from 86 in 2008, to 133 in 2009 and to 137 in 2010.
Figure 1.  Research subjects of national drug-related studies cited in the 2008, 2009 
and 2010 Reitox national reports (percentage of all studies cited)
Responses, 34%
Consequences of 
drug use, 26% 
Supply and markets, 5%
Determinants and risk or 
protective factors, 4% 
Methodology, 3%
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Mechanisms and effects 
of drugs, 4% 
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Figure 2.  Research subjects of national drug-related studies cited in the 2008, 2009 
and 2010 Reitox national reports (absolute figures per year)
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NB: In 2008, 372 references for the years 2006–08 were cited in 26 national reports; in 2009, 671 references for 
the years 2007–09 were cited in 29 national reports; in 2010, 765 references for the years 2008–10 were cited in 
28 national reports.
Interpretation of the results
After the first data collection and analysis had been completed in 2009, a memo was prepared for 
the Reitox national focal points explaining the objectives of this exercise and its methodology, and 
containing recommendations for the reporting of research activities in the national reports. While 
the increase in the number of cited research studies observed between 2009 and 2010 may reflect 
an actual increase in the number of drug-related research studies carried out, it is also possible that 
it reflects to some extent an increased awareness of the exercise. In addition, the topics chosen for 
the EMCDDA Selected issues (7) for each reporting year may have also contributed to the increase 
observed in the number of cited studies in research areas linked to these topics, especially because 
some research studies were carried out specifically to fill in evidence gaps for the topics covered in 
the Selected issues. As such, it may be interesting to assess how responses of national focal points 
to the reporting needs of the EMCDDA influence research in Member States in areas where 
evidence is lacking.
As Reitox national reports are drafted according to topics and guidelines agreed between the 
EMCDDA and the Reitox focal points and with the ultimate aim of meeting the EMCDDA’s reporting 
needs, not all areas of drug-related research may be represented equally in the national reports. 
(7)  The Selected issues are in-depth reviews of topical interest. They are based on information provided to the 
EMCDDA by the Reitox national focal points as part of the national reporting process and are targeted at 
policymakers and their advisors as well as specialists and practitioners in the drugs field.
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For instance, while there is ample citation, and sometimes even full description, of research related 
to the drugs situation and responses to it, studies on the neuroscience of drug use are rarely 
reported, even in countries where this research in known to be carried out. In addition, the 
information reported on research outputs depends on the availability of such information at the 
national focal points. As finding and categorising information for the analysis described above 
depends on the use of a limited number of keywords and correct bibliographic referencing, some 
references may have been mistakenly excluded or misclassified. However, due to the validation 
process, this exclusion or misclassification may have been minimal.
Usage statistics about the thematic web area, where information on drug-related research in 
Europe is accessible to the general public and the scientific community, have been collected since 
September 2009. These logs show an increase in visits from all over the world, with an average of 
more than 300 visits per month between September 2009 and December 2011. The results of this 
analysis have been presented in EMCDDA publications, as well as in country overviews — which 
are updated on a regular basis — and in presentations to the Horizontal Working Party on Drugs’ 
annual dialogue on research. Furthermore, input based on these results is given, on demand, to the 
European Commission, the Council and Parliament, national funding programmes, national experts, 
EU presidency initiatives, and European projects and conferences. Overall, this data collection 
exercise has proven to be useful to several stakeholders, ranging from the national focal points to 
EC-funded projects, potential applicants to FP7 and other programmes’ calls, and decision-makers 
at European and national level.
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Conclusions and implications for future work
European research cooperation complements and adds value to national research (Bühringer et al., 
2009; EMCDDA, 2008). The drugs problem knows no borders, and cross-border aspects of the 
drugs problem must be researched and tackled at a multinational level. At European level, it is 
possible to launch large-scale, multi-site and longitudinal studies that enable more powerful analysis 
of key aspects of the drug phenomenon, such as the causes of onset of drug use or dependence, or 
the influence of different social, cultural and economic factors on drug use. Furthermore, research 
coordinated at European level may take a multidisciplinary approach and cover a diversity of 
disciplines that may not all be available in one country.
An efficient and coherent drug-related research policy is based on an understanding of the 
different agendas or objectives of research and policy. Policymakers want rapid and unambiguous 
answers. Science takes time and gives relative truths. Science enables policymakers to understand 
the drug situation, and scientists draw important research topics from the political agenda. 
Although policymakers and researchers often have different agendas and priorities, they may all 
benefit from well-functioning multidisciplinary research networks producing policy-relevant output at 
national and EU level (Garretsen et al., 2010).
The overall developments in recent years are encouraging. Studies and research findings are 
increasingly being used by EU Member States, European collaboration is being promoted by EU 
bodies, research projects and societies and a number of other initiatives, such as collaborative 
academic centres (Garretsen et al., 2010), drug-related scientific paper awards and academic 
summers schools, are contributing to ‘promote, coordinate and improve more addiction research in 
Europe and to make its usefulness clearer to policy, public health and the general public’ 
(Bühringer, 2012). However, there is still room for further improvement, and continuity and 
sustainability of the reported developments need to be ensured.
Well-functioning coordination between research and political decision-making is a prerequisite for 
sustainable, comprehensive and relevant research, but also for knowledge transfer among the 
scientific community, between research and practice and between science and the decision-making 
process (EMCDDA, 2008). To promote dialogue and coordination, mechanisms such as public 
hearings and consultations, such as the 1996 joint seminar on ‘Drug research-related initiatives in 
the European Union’, organised by the European Commission, could be developed for 
policymakers, civil society (through research associations, for example) and scientists to voice their 
needs and promote a common understanding of evidence gaps and a long-term, comprehensive 
research strategy. Having a stable funding strategy and framework for research at national and EU 
level would optimise investments in this area and would allow for more synergies to be created. 
Accessibility of research is also an important consideration for an efficient use of the findings and 
for the allocation of resources. Research results should be made available widely and promptly, 
preferably in different languages, to professionals and policymakers, so that they can be put into 
practice.
There are potentially large resources available for drug-related research if research and policy join 
forces across the European Union. Member States may cooperate to establish a platform for the 
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identification of priorities for research in the drugs field and the development of a joint strategy, 
which would lead to the pooling of resources and the launch of joint research projects, and 
enhance collaboration between researchers from different countries. The forthcoming ERANID 
project (see ‘Drug-related research: definitions and implementation aspects’) is a step in this 
direction. Sustainability, however, needs to be ensured even in those areas that currently account 
for much of the research activity. And more needs to be done to match the current research efforts 
with adequate funding (Bühringer, 2012). The existence of high-quality national research 
programmes and structures is particularly important if Europe is to establish a sustainable multi-
national scientific community that may support evidence-based practice and policy in the future. 
The new EU common strategic framework for research, Horizon 2020, will start in 2014 to address 
both research and innovation. This framework has the potential to promote coordination in the 
funding of multidisciplinary areas, such as drug-related research.
The methodology developed by the EMCDDA to collect information on drug-related research 
through Reitox national reports has been proven to be a valuable monitoring exercise, used by 
several stakeholders in the field. The results reveal two major findings: during the period studied, 
the number of references to ongoing research or studies increased, and the majority of studies were 
conducted in three areas (prevalence, incidence or patterns of drug use; responses; and 
consequences of drug use). This contribution could be further developed to provide continued 
support to decision-makers at European and national level. The EMCDDA may also work to provide 
further support to the European scientific community, national and European funding programmes 
and European research projects, in order to further promote synergies, avoid overlaps and increase 
the dissemination of research resources and research findings.
The changing nature of European drug problems, together with the growing importance of the 
Internet and mobile communication, present both challenges and opportunities for research. 
Research into the changing patterns of drug use, drug-related public expenditure, and the cost-
effectiveness of interventions is especially required, as budget cuts and financial concerns across 
Europe focus attention on the need to understand the relative benefit to cost of different policy 
options.
The EMCDDA and its Scientific Committee are committed to contributing to this process through a 
proposal for an agreed methodology for identifying evidence gaps in the research. Such an 
evidence-based, systematic approach could be an important tool to support both EU institutions (for 
example, the Horizontal Working Party on Drugs, through its annual dialogue on research) and 
national stakeholders.
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